EPRXEupraxia Pharmaceuticals Inc.
What is the market doing?
Rangebound. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Rangebound, no clear trend. Price is −7% vs its 200-day average.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How EPRX is trading
Eupraxia Pharmaceuticals Inc. is +25% over the past year while the S&P 500 is +16%: 8.9 points ahead of the market.
1-year return · S&P 500 +16%
- vs 200-day average
- −6.6%
vs 200-day average · below trend, but not far
- RSI (14)
- 38
RSI (14) · neutral
- Below its 52-week high
- 25%
Below its 52-week high
Details›
- Last close2026-10-23
- $6.86
- 1 monthS&P 500 −0.94%
- −16%
- 1 yearS&P 500 +16%
- +25%
- vs 50-day average$7.57
- −9.4%
- 52-week high
- $9.12
- 52-week low
- $5.33
- Annualised volatility
- 67%
| Year | Return |
|---|---|
| 2026 (year to date) | −9.2% |
| 2025 | +138% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 2 | 1 of 2 | +0.51% |
| Feb | 2 | 1 of 2 | +19% |
| Mar | 2 | 0 of 2 | −15% |
| Apr | 2 | 2 of 2 | +16% |
| May | 3 | 0 of 3 | −5.2% |
| Jun | 3 | 1 of 3 | +12% |
| Jul | 3 | 1 of 3 | +0.24% |
| Aug | 3 | 1 of 3 | −3.4% |
| Sep | 3 | 3 of 3 | +18% |
| Oct | 3 | 0 of 3 | −12% |
| Nov | 2 | 2 of 2 | +23% |
| Dec | 2 | 1 of 2 | +8.1% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.
Biotechnology
The closest names by size in the same industry